

A rising leader of precision medicine

The biomedical high-tech company, **GENEIS**, IS STRIVING TO BE A LEADER in the precision medicine era.

Individualized care is the goal for the new era of medicine.

In 2015, the then US president, Barack Obama announced in his State of the Union Address the launch of the Precision Medicine Initiative, a new research project in biomedicine that aims to revolutionize our approach to treat diseases, particularly cancer and diabetes. China, too, set precision medicine and life sciences as an industry of national strategic importance in its 13th five-year plan (2016-2020) for the country's economic and social development in March 2016.

In the trend of the flourishing of precision medicine, Geneis,

a cutting-edge biotechnology company was born in Zhongguancun, Beijing's high-tech hub. With genomics and bioinformatics at its core, it builds precision medicine platforms for cancer and is dedicated to applying advanced genomic technologies to clinical use, providing more reliable and personalized medication plans for patients.

Currently, Geneis has six core patented technologies, including Tcap, Decap and Ucap technologies, as well as copyrights for eight software packages. Based on these strengths, it has developed liquid biopsy series, 10K, which can achieve a sensitivity




of 1 out of 10 thousand with only 10 ml of peripheral blood. Innovation by Geneis also includes more than 150 products for the diagnosis and treatment of cancer, featuring early screening and diagnosis, precision medication and prognosis evaluation. The highlights are its series of genetic testing products, including GeneCAN, GeneCURE and GeneCARE, which are aimed at achieving the ultimate goal of liquid biopsy, providing qualitative, quantitative, traceable and determinable information for cancer therapy.

The establishment of the Geneis medical laboratory, approved by the Chinese National Health and Family Planning Commission, has provided an integrated software and hardware platform for the analysis of medical big data. Geared towards clinical application, the laboratory has built a collaborative centre with nation-wide networks for precision medicine, along with a tumour bank and a database.

Geneis pioneered in China the business model of collaborating with hospitals to co-establish a support

system for precision medicine, leading to the establishment of precision medicine centres in partnership with more than 30 premier tumour hospitals in major cities. With complete technical platforms and a full set of diverse cancer products, Geneis's comprehensive system of molecular testing has provided solutions to molecular typing and diagnosis, continuing care and medical management of cancer.

More than 40% of the 200-plus staff of the company have obtained Master's or doctoral degrees. With a productive, energetic and well-structured research team, the company has won dozens of honours, such as the 'frontier technology enterprise of Zhongguancun' and the 'Intel precision medicine partner'. Geneis has provided precision medicine solutions to hundreds of thousands cancer patients nation-wide, reducing their pain and improving their quality of life. ■



400-860-8065
service@geneis.cn
<http://www.geneis.cn>